

***Draft Vaccine Recommendations for
the West Eurasia Roadmap***

ARRIAH, SAP Institute and TPI

Vaccine selection should carefully consider the following FMDV lineages:

Circulating in the region - O/ME-SA/PanAsia-2, A/ASIA/Iran-05, A/ASIA/G-VII, Asia-1/Sindh-08.

Circulating in the neighbourhood - O/ME-SA/Ind2001 (sporadically in the Gulf States), A/ASIA/Sea-97 (via East Asia), O/ME-SA/PanAsia (via East Asia and recently in Israel and the Palestinian Autonomous Terr.) and SAT 2 (sporadically in the Gulf States)

Serotype O

- ***O TUR/5/2009*** (or equivalents from local suppliers), ***O TUR/2007*** (or equivalent from local suppliers), or ***O 3039*** (in combination with ***O1 Manisa***) for O/ME-SA/PanAsia-2

Serotype O

[1] Vaccine matching data suggest that some circulating strains have poor match with O1 Manisa

[2] Where tested, these vaccines have also been recommended for use against the O/ME-SA/Ind2001 lineage from the Indian sub-continent that has caused recent outbreaks in the Middle East and North Africa

[3] For countries bordering China, it is advisable to consider addition vaccine components that cover O/ME-SA/ PanAsia and O/SEA/Mya-98 in the vaccine formulation

Serotype A

- ***A TUR/06 (or equivalent from local suppliers) or A Iran 05 for A/ASIA/Iran-05***
- ***for the emerging A/ASIA/G-VII lineage - Turkish vaccine A/ASIA/G-VII-TUR15***

Serotype A

[1] Vaccine matching data suggest that some circulating A/ASIA/Iran-05 field strains have poor match with these vaccines.

*[2] Many established vaccines are not expected to provide protection against the A/ASIA/G-VII lineage. Tailored vaccines, **A/ASIA/G-VII-TUR15**, for this emerging lineage have become recently available from a local supplier (Turkey), and are anticipated shortly from other manufacturers. Field vaccine evaluation of these products is pending.*

[3] For countries bordering China, it is advisable to consider addition vaccine components that cover A/ASIA/SEA-97 in the vaccine formulation

Asia 1

- ***Asia 1 (Sindh-08) or closely related strains or Asia 1 Shamir at high potency.***

Notes:

[1] Asia 1 Samir only has poor in-vitro antigenic match against the current circulating Sindh-08 lineage. However, in-vivo experiments indicate that poor antigenic match can be compensated by high potency formulations (>6PD50).